Optimization of CRT Using an ECG Vest

Sponsor
Alan J. Bank, MD (Other)
Overall Status
Completed
CT.gov ID
NCT02699944
Collaborator
Medtronic (Industry)
56
1
1
69.5
0.8

Study Details

Study Description

Brief Summary

Despite advancements in implant technology and various techniques of optimization, there is still around 30% non-responder rate to cardiac resynchronization therapy (CRT). This study will assess the potential benefit of a body surface mapping technology to optimize CRT devices in the chronic sub-optimal responder setting.

Condition or Disease Intervention/Treatment Phase
  • Device: ECG Vest Optimization
N/A

Detailed Description

Cardiac resynchronization therapy (CRT) is one of the most important advances in the treatment of patients with heart failure (HF). This therapy, also known as biventricular pacing, utilizes pacemaker leads to synchronize the contraction of the walls within the left ventricle (LV) and the contraction of the left and right ventricles. Many randomized trials have conclusively demonstrated that CRT improves symptoms, LV structure and function, hospitalization rates, and survival in appropriately selected HF patients. Nonetheless, approximately 30% of CRT patients will be "non-responders" because they will not demonstrate the expected clinical and/or echocardiographic improvement following therapy. A critical component of assessing CRT efficacy during the optimization clinic will be the use of a novel method of body surface electrocardiographic mapping under development by Medtronic, called the ECG Vest. In this proposal, we describe a research study to assess the potential benefit of using the ECG Vest as part of a CRT optimization strategy on clinical and echocardiographic outcomes (heart size and function) of patients receiving standard clinical care in the UHVC CRT Optimization Clinic.

Study Design

Study Type:
Interventional
Actual Enrollment :
56 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Optimization of Cardiac Resynchronization Therapy Using an ECG Vest
Actual Study Start Date :
Nov 1, 2015
Actual Primary Completion Date :
Aug 17, 2021
Actual Study Completion Date :
Aug 17, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: CRT sub-optimal responder

Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still <50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.

Device: ECG Vest Optimization
As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.

Outcome Measures

Primary Outcome Measures

  1. Change in left ventricular end-systolic volume [6 months after optimization]

Secondary Outcome Measures

  1. Determine the degree to which echocardiographic measures of LV function correlate with ECG Vest measures [6 months after optimization]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients (or their legal guardian) must be willing to provide Informed Consent and a data privacy (HIPPA) authorization

  • Patient is or will be followed clinically in the UHVC CRT Optimization Clinic

  • Patient has been implanted with a CRT device for at least 6 months

  • Patient received an echocardiogram prior to CRT implant

  • Patients must be ≥ 18 years of age

Exclusion Criteria:
  • Patient's EF is currently ≥ 50%

  • Patients who are pregnant

  • Patient has unhealed / open wounds on the torso and/or has a history of severe allergic reactions from ECG gel / electrode glue

Contacts and Locations

Locations

Site City State Country Postal Code
1 United Heart & Vascular Clinic Saint Paul Minnesota United States 55102

Sponsors and Collaborators

  • Alan J. Bank, MD
  • Medtronic

Investigators

  • Principal Investigator: Alan J Bank, MD, Medical Director of Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alan J. Bank, MD, Medical Director of Research, Allina Health System
ClinicalTrials.gov Identifier:
NCT02699944
Other Study ID Numbers:
  • 767654-1
First Posted:
Mar 7, 2016
Last Update Posted:
Sep 23, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 23, 2021